Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of CanBas Co., Ltd.. A complete text table follows the diagram.
The pre-revenue biotech puts most operating expense into clinical and discovery work while cash funds the path toward a larger trial.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research & development expenses | 1 | 445M | 74.1% of reported total |
| Selling, general & administratibe expenses | 1 | 155M | 25.9% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Operating expenses | 2 | 600M | Reported six-month total · ¥600M |
| Operating loss | 2 | 600M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 1.2B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research & development expenses | Operating expenses | 445M |
| Selling, general & administratibe expenses | Operating expenses | 155M |
| Other & rounding | Operating expenses | 0 |
| Operating expenses | Operating costs & expenses | 600M |
| Operating loss | Operating costs & expenses | 600M |